Living with Multiple Sclerosis in Europe: Pharmacological Treatments, Cost of Illness, and Health-Related Quality of Life Across Countries

Abstract

More than 700,000 people suffer from multiple sclerosis (MS) in Europe. This implies that more than 1 million people are affected by this disease through their role as caregivers and family members. Given its relevant impact, MS deserves consideration by epidemiologists, clinicians, psychologists, social scientists and other scholars. Such interdisciplinarity is stressed in the present contribution, which focuses on various aspects of socioeconomic burden. Starting from considerations about the epidemiology of the disease in Europe, as outlined by the MS Barometer, a comparative survey based on data collected by the national MS societies and launched in 2008, a brief literature review for each European country mentioned in the report was carried out with the following key terms: "multiple sclerosis," "cost of illness," and "health-related quality of life (HRQoL)." The consideration of the level of assistance provided, the access to rehabilitation centers, and the availability of pharmacological treatments, Drugs, Costs and Quality of Life for MS Patients in Europe 18especially innovative therapies, reveal how there are still huge differences across Europe. Literature contributions are mostly oriented toward HRQoL studies and the impact of new pharmacological treatments. There are less studies focusing on compliance: this may be the consequence of a higher awareness of the disease among the patients and a strengthened cooperation with the physicians. Some suggestions about foreseeable and desirable lines of research conclude the contribution.

The Association Between Sexual Disorders and the Quality of Life of Woman Patients With Multiple Sclerosis: Findings of a Prospective, Observational, and Cross-Sectional Survey

“…Multiple sclerosis (MS) is a progressive, chronic inflammatory demyelinating disease of the central nervous system on which suffer about 2.3 million people worldwide, 1 more than 700,000 in Europe. 2 In Poland, the MS rate is quite high about 110e120 per 100,000 inhabitants. 3,4 MS is most often diagnosed in people between 20 and 40 years of age.…”

Predictors of Multiple Sclerosis Severity Score in Patients with Multiple Sclerosis

“…In recent years, patient awareness of life style and dietary factors affecting MS severity has increased as reflected by better MS survival rates, however this observation remains limited to developed countries. 22,23 In Kuwait, obesity and a sedentary lifestyle have become commonplace and in 2016 the prevalence of obesity in Kuwait was estimated to be 42.4%. 24 In an observational study conducted on 212 Kuwaiti MS patients we noted that 60.8% of MS patients were overweight/obese (data unpublished).…”

Where mitoxantrone for multiple sclerosis is still valuable in 2018

“…The relatively affordable mitoxantrone currently retains high importance for the treatment of inflammatory very active MS in regions with limited general access to more expensive newer second‐line MS immunotherapies. These restrictions still also apply to parts of Europe despite significant improvements during recent years .…”